Diffuse cutaneous systemic sclerosis ("dcSSc") is a rare, progressive autoimmune disease characterized by immune activation, vasculopathy and fibrosis affecting the skin and internal organs, including ...
Aisa Pharma, Inc., a clinical-stage biopharmaceutical company focused on therapies for systemic sclerosis, today announced results from its Phase 2 RECONNOITER trial of AISA-021 (cilnidipine), a novel ...
The prevalence of SSc among Alaska Native and American Indian adults is comparable to or higher than other populations, with high GI and pulmonary involvement.
Initial $50M Series A investment from founding investor RTW InvestmentsProceeds will fund clinical development of PRO-203 in systemic sclerosis ...
Nutritional issues such as ARFID are highly prevalent among patients with SSc and can lead to poor outcomes and other systemic complications.
London, UK – 3 March, 2026 – Quell Therapeutics Ltd (“Quell”), today announced that it has initiated a Phase 1/2 basket clinical study evaluating ...
Please provide your email address to receive an email when new articles are posted on . Patients with systemic sclerosis had increased risk for hematologic and solid organ cancers at 5 years vs. a ...
A retrospective cohort study found that beta-blocker use is associated with a decreased risk for incident HF in certain SAID populations.
A nationwide Swedish register-based study revealed that individuals with systemic sclerosis had a higher risk for hematologic malignancies. Myeloid malignancies typically presented around disease ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results